Kuros Biosciences AG
/ Key word(s): Annual Results
- Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024. Following the announcement, the company will host a video conference call at 3pm CET/10am US EST to discuss the results. To register for the video call, click here. For further information, please contact:
About Kuros Biosciences
End of Media Release |
Language: | English |
Company: | Kuros Biosciences AG |
Wagistrasse 25 | |
8952 Schlieren | |
Switzerland | |
Phone: | +41 44 733 4747 |
Fax: | +41 44 733 4740 |
E-mail: | info@kurosbio.com |
Internet: | www.kurosbio.com |
ISIN: | CH0325814116 |
Valor: | 32581411 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1854131 |
End of News | EQS News Service |
|
1854131 08.03.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.